Search Results - "BIGENZAHN, W"

Refine Results
  1. 1
  2. 2
  3. 3

    Recent advances in combinatorial drug screening and synergy scoring by Pemovska, Tea, Bigenzahn, Johannes W, Superti-Furga, Giulio

    Published in Current opinion in pharmacology (01-10-2018)
    “…•Currently a vast heterogeneity in synergistic drug action scoring and analysis exists.•Novel cellular models offer robust ways to identify relevant…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis by Fauster, A, Rebsamen, M, Huber, K V M, Bigenzahn, J W, Stukalov, A, Lardeau, C-H, Scorzoni, S, Bruckner, M, Gridling, M, Parapatics, K, Colinge, J, Bennett, K L, Kubicek, S, Krautwald, S, Linkermann, A, Superti-Furga, G

    Published in Cell death & disease (01-05-2015)
    “…Necroptosis is a form of regulated necrotic cell death mediated by receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3. Necroptotic cell…”
    Get full text
    Journal Article
  7. 7

    Metabolic drug survey highlights cancer cell dependencies and vulnerabilities by Pemovska, Tea, Bigenzahn, Johannes W., Srndic, Ismet, Lercher, Alexander, Bergthaler, Andreas, César-Razquin, Adrián, Kartnig, Felix, Kornauth, Christoph, Valent, Peter, Staber, Philipp B., Superti-Furga, Giulio

    Published in Nature communications (14-12-2021)
    “…Interrogation of cellular metabolism with high-throughput screening approaches can unravel contextual biology and identify cancer-specific metabolic…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Identifying Kinase Substrates via a Heavy ATP Kinase Assay and Quantitative Mass Spectrometry by Müller, André C., Giambruno, Roberto, Weißer, Juliane, Májek, Peter, Hofer, Alexandre, Bigenzahn, Johannes W., Superti-Furga, Giulio, Jessen, Henning J., Bennett, Keiryn L.

    Published in Scientific reports (27-06-2016)
    “…Mass spectrometry-based in vitro kinase screens play an essential role in the discovery of kinase substrates, however, many suffer from biological and…”
    Get full text
    Journal Article
  11. 11
  12. 12

    High risk of unilateral recurrent laryngeal nerve paralysis after esophagectomy using cervical anastomosis by Pertl, L., Zacherl, J., Mancusi, G., Gächter, J. N., Asari, R., Schoppmann, S., Bigenzahn, W., Schneider-Stickler, B.

    Published in European archives of oto-rhino-laryngology (01-11-2011)
    “…The goal of this study was to estimate the incidence of temporary and permanent unilateral recurrent laryngeal nerve paralysis (URLNP) after esophagectomies…”
    Get full text
    Journal Article
  13. 13

    Superimposed high-frequency jet ventilation (SHFJV) for endoscopic laryngotracheal surgery in more than 1500 patients by Rezaie-Majd, A., Bigenzahn, W., Denk, D.-M., Burian, M., Kornfehl, J., Grasl, M.Ch, Ihra, G., Aloy, A.

    Published in British journal of anaesthesia : BJA (01-05-2006)
    “…Superimposed high-frequency jet ventilation (SHFJV), which does not require any tracheal tubes or catheters, was developed specifically for use in…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3 LZTR1 E3 Ligase KRAS Complex by Piech, Sophie, Brüschweiler, Sven, Westphalen, Josepha, Siess, Katharina M, García Murias, Julio, Konrat, Robert, Bigenzahn, Johannes W, Superti-Furga, Giulio

    Published in ACS chemical biology (20-09-2024)
    “…The RAS family of GTPases is among the most frequently mutated proteins in human cancer, creating a high clinical demand for therapies that counteract their…”
    Get full text
    Journal Article
  17. 17

    Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3LZTR1 E3 Ligase KRAS Complex by Piech, Sophie, Brüschweiler, Sven, Westphalen, Josepha, Siess, Katharina M., García Murias, Julio, Konrat, Robert, Bigenzahn, Johannes W., Superti-Furga, Giulio

    Published in ACS chemical biology (20-09-2024)
    “…The RAS family of GTPases is among the most frequently mutated proteins in human cancer, creating a high clinical demand for therapies that counteract their…”
    Get full text
    Journal Article
  18. 18

    How we do it: Voice therapy to improve vocal constitution and endurance in female student teachers by Schneider, B., Bigenzahn, W.

    Published in Clinical otolaryngology (01-02-2005)
    “…Keypoints • Vocal hypofunction should be regarded as risk factor of occupational voice disorders. • Voice therapy is effective to improve vocal endurance and…”
    Get full text
    Journal Article
  19. 19
  20. 20